This trial is testing a new treatment for patients with early stage lung cancer who cannot have surgery. The goal is to see if it is a good option for these patients.
- Non-Small Cell Lung Cancer
1 Primary · 6 Secondary · Reporting Duration: 24 months
Awards & Highlights
1 Treatment Group
Chemotherapy with hypofractionated RT
1 of 1
12 Total Participants · 1 Treatment Group
Primary Treatment: Carboplatin · No Placebo Group · Phase < 1
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What maladies has Paclitaxel been traditionally prescribed for?
"Paclitaxel is the go-to medication for treating melanoma. Moreover, it can also assist with other diseases such as metastasized neoplasms, lymphomas, non-Hodgkin's malignancies and advanced sarcoma." - Anonymous Online Contributor
Are there still openings for volunteers in this trial?
"This clinical study, initially released on December 1st 2014 and most recently updated May 1th 2018, is seeking participants. Clinicaltrials.gov has the information available for public viewing." - Anonymous Online Contributor
How many participants are enrolled in this investigation?
"Affirmative. The clinical trial directory on clinicaltrials.gov shows that recruitment for this medical study is active - it was initially posted on December 1st 2014 and its information has been recently updated as of May 1st 2018. At present, 12 participants need to be found from a single clinic site." - Anonymous Online Contributor
Has Paclitaxel been evaluated in other clinical trials?
"At present, there are 1175 active Paclitaxel studies with 332 of those in the 3rd phase. Notably, Shanghai alone has several clinical trials while globally 66531 different locations have a trial running for this medication." - Anonymous Online Contributor